I need the answers to this case study about marginal cost pricing

3/25/09 Case 2 University Hospital (Marginal Cost Pricing) University Hospital is a regional leader in the very intense and medically sophisticated area of organ transplants. Mark Lewis, the director of the Transplant Center, has been with the Hospital for ten years. When Mark joined the hospital, he was put in charge of a kidney and heart transplant program that averaged 50 transplants per year. Today, the Transplant Center performs over 200 transplants annually, including transplants from the newly initiated liver, lung, and pancreas programs. The liver transplant program is the most successful of all organ programs in terms of volume and revenues. Last year, volume totaled 100 transplants, and this year Mark is optimistic that the liver program can do even better. However, he knows that increased volume is largely dependent on the number of organ donors and his success in negotiating a new contract with the Transplant Management Corporation (TMC), the largest transplant-benefits company in the nation. Because transplants are relatively rare in comparison with other, more conventional medical treatments, only the largest health insurers have the expertise to manage transplant services. However, the costs to insurers for transplant services are typically very largeusually in the six-to-sevenfigure range. To ensure the best and most cost-effective management of transplant services, most health insurers outsource transplant management to companies, such as TMC, that specialize in these services. Contracting for transplant services is unique and complex because of the sophistication of the medical procedures involved. Transplant services consist of five phases: (1) patient evaluation, (2) patient care while awaiting surgery, (3) organ procurement, (4) surgery and the attendant inpatient stay, and (5) one year of follow-up visits. The costs involved in Phase 1 are relatively simple to estimate, but the remaining phases can be extremely variable in terms of resource utilization, and hence costs, because of differences in patient acuity and surgical outcomes. Historically, reimbursement for transplant services has been handled in a number of different ways. Initially, many providers bundled all five phases together and offered insurers a single, global rate. Although this method simplified the contracting process, the rate set was often chosen more on the Copyright 2009 Health Administration Press basis of building market share than on covering costs. Indeed, many providers could not even estimate with any confidence the true costs of providing transplant services. Somewhat ironically, success in gaining market share usually increases the financial risk of the transplant program because higher volumes increase the likelihood of higher acuity patients. Although the total costs associated with all phases of a liver transplant average about $400,000, the amount can more than quadruple if the patient requires a re-transplant or if other complications occur. Because of this extreme variability in costs, outlier protection is a critical aspect of contract negotiations if the reimbursement methodology is a fixed prospective rate. Thus far, several elements of the proposed contract with TMC have been finalized. Specifically, Phases 1, 2, and 5 will be reimbursed at a set discount from charges. Furthermore, to reduce the amount of financial risk borne by University Hospital, Phase 3 (organ procurement) will be reimbursed on a cost basis. This makes sense because the cost of Phase 3 is almost completely uncontrollable by the Center. In general, Phase 4 costs are divided into two categories: hospital costs and physician costs. Physician costs have already been agreed on, so what needs to be hammered out (and the make-or-break part of the contract) is the hospital reimbursement amount for Phase 4. The key to a sound negotiation with TMC is to identify relevant costs. Mark plans to be aggressive in pricing these services, because he wants the contract. He feels that the additional volume will lower per-transplant cost and hence increase the Center's profitability. Still, he wants to set a price that does not degrade the current profitability of the Center, which is good but not spectacular. To help with the decision, Mark compiled the Phase 4 hospital costs of 12 recent liver transplant patients. In reviewing these data, shown in Table 1, Mark noted that a total average cost of $119,805 for 19 days' average length of stay (LOS) translates to a staggering per diem (per day) average cost of over $6,000. Mark is convinced that a price close to $120,000, which would cover total costs, would not be acceptable to TMC. So, he examined the possibility of lowering costs by reducing the average LOS. However, the costs associated with Phase 4 are not a linear function of LOS. The first day of Phase 4 is usually the most costly, whereas the last day is usually the least costly. Indeed, over half of Phase 4 costs occur in the first 24 hours of hospitalization. Because it would be difficult to lower Phase 4 hospital costs by reducing LOS, Mark decided to pursue a different strategy. His experience at the Copyright 2009 Health Administration Press Transplant Center has convinced him that there are economies of scale present in liver transplants, and hence the marginal cost of each transplant is lower than the average cost. Thus, Mark believes that he can base the contract price on marginal costs rather than total (full) costs. Such a rate would (hopefully) be attractive to TMC yet, at the same time, preserve the Center's profitability. Assume that you have been hired as a consultant to recommend a fixed price (the base rate) that should be proposed in the contract negotiations for Phase 4 hospital services. To help in the analysis, Mark has indicated that approximately 60 percent of nursing, ancillary, operating room, and laboratory costs are fixed. The remaining costsradiology, drug, and other servicesare predominantly variable. TABLE 1 University Transplant Center Phase 4 Hospital Costs A B C D E F G H I J K L Average Age LOS Total Costs Nursing Cost Ancillary Cost OR Cost Lab Cost Radiology Cost 61 56 42 52 12 59 41 35 52 38 59 60 Patient Drug Cost Other Costs 25 15 12 13 26 22 25 17 12 13 25 21 $141,092 139,306 74,259 115,349 172,613 83,807 136,060 139,308 74,259 115,348 166,224 80,034 $10,261 11,969 6,939 7,221 28,205 16,858 9,645 11,969 6,939 7,221 26,909 15,629 $65,416 63,668 33,661 54,063 72,204 33,474 63,208 63,669 33,660 54,063 69,657 32,202 $6,770 8,501 3,128 5,779 6,847 4,654 6,489 8,501 3,128 5,778 6,765 4,531 $13,712 7,409 5,279 6,112 10,550 6,211 13,091 7,409 5,280 6,111 10,061 5,937 $1,483 2,261 668 903 1,766 1,397 1,382 2,261 668 903 1,677 1,293 $20,992 24,504 6,964 7,638 23,061 9,698 20,127 24,505 6,964 7,639 22,007 9,122 $22,458 20,994 17,620 33,633 29,980 11,515 22,118 20,994 17,620 33,633 29,148 11,320 47 19 $119,805 $13,314 $53,245 $5,906 $8,097 $1,389 $15,268 $22,586 QUESTIONS 1. What is the estimate of the marginal cost of the Phase 4 hospital services assuming, as given in the case, that 60 percent of the designated costs are fixed and the remaining costs are variable? 2. Assume that the agreed-upon price is $90,000. What is the expected profit on the contract assuming that it brings in 20 new patients? (Assume for now that no new fixed costs would be required.) Copyright 2009 Health Administration Press 3. Now assume that the additional patients will add $200,000 in total to the Center's fixed costs. Now what is the expected profit on 20 new patients? On 40 new patients? (No new fixed costs are required to support the second group of 20 patients.) 4. What role do the following factors play in the decision regarding whether to use marginal cost pricing on the new contract? a. Reimbursement amounts paid by current transplant third-party payers b. The amount of excess capacity in the transplant unit c. The potential reaction by current payers to a new, lower-price contract 5. What is your final recommendation regarding the base rate for Phase 4 hospital services that should be built into the contract? 6. Should you worry only about the contract's first year pricing, or should you develop a long-term pricing strategy for TMC? What are some possible features of a long-term pricing strategy? 7. Briefly describe how outlier payments might be handled to ensure that the Center does not suffer large losses on outliers (patients with unusually high costs). (Hint: Cost outliers are identified by having costs that exceed a specified threshold. Then, in addition to the standard payment, the provider is reimbursement for some percentage of the costs above the threshold. For this question, you must choose a cost threshold and outlier payment percentage.) Copyright 2009 Health Administration Press \fUniversity Center Hospital Case Analysis Marginal Cost Analysis Category Average Cost ($) Nursing 13,314 Ancillary 53,245 OR 5,906 Laboratory 8,097 Radiology 1,389 Drug 15, 268 Other 22, 586 Total 119,805 Therefore, the marginal cost is 0.6 x 119, 805. Therefore, the marginal cost estimate is $ 71,883. Expected Profit Total revenue from the agreed price, $90,000 x 20 patients= $1, 800, 000 Less: total costs incurred (M.C) ($71,883x20patients) =$1, 437, 660 $362, 340 3. Expected profit for the additional patients Total revenues less total costs = $1, 800,000 less ($1, 437, 660+$200,000) = $162, 340. Total revenues from 40 patients, $90,000 x 40 patients = $3,600,000 Less: total costs = ($2,875, 680) $724,680 a. The nature of the reimbursement amounts paid by the current transplant third party payers could also affect the contracting process that in turn questions the use of the marginal cost pricing strategy. The third payers also set the rate of covering the transplant costs that cannot be easily estimated. b. The level and amount of excess capacity in the transplant unit helps in determining the most cost effective approach for the management of the transplant services. Thus, it helps in determining whether to adopt the marginal cost pricing due to the inherent excess capacity in the transplant department. c. The potential reaction by current payers to the new lower price contract factor helps in evaluating the suitability of using the marginal cost pricing in Phase 4 services. Finally, I would recommend the Transplant Center to build the contract based on the marginal cost rate. The marginal costs are usually lower than the average costs and thus, it promotes the profitability of the Center. I think it is important to develop a long-term pricing strategy for the contract. The long-term strategy would help in optimizing the profits and costs incurred in TMC in relation to the goals of the company. Some of the possible features of a long term pricing strategy include it set prices that match the value of the health care services, the strategy should also be profitable, it must also emphasize on superior service quality, and lastly, the strategy should be able to cover a large share of the markets. The outlier payments might be handled by limiting the charge of excess costs to the standardized rates in the contract of TCM. Existing regulations also limits a certain level of health care costs billing per patients in order to avoid the outlier payments. The outlier payment should be 80 per cent of the excess over the large losses suffered from the outliers. 6 per cent of the standardized payments would be a realistic outlier payment percentage to reduce the increased costs to the hospitals. A cost threshold of $33,560 per case would be help in limiting the excess costs to be incurred by the hospitals after reimbursements